Insmed Reports Third Quarter 2015 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall, dragged by Alphabet and megacap tech; focus on Iran
- Oil falls almost 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
UBS Downgrades Insmed (INSM) to Neutral; Arikayce Becomes a 2017 Story
November 9, 2015 7:59 AM ESTUBS downgraded Insmed (NASDAQ: INSM) from Buy to Neutral with a price target of $18.00 (from $35.00) based on a SOTP as Arikayce becomes a 2017 story.
Analyst Matthew Roden commented, "Insmed reported 3Q results and an incrementally negative update to the enrollment progress... More
US NTM Delayed Up to 12 Months; Cowen Cuts Price Target on Insmed (INSM) to $34
November 9, 2015 6:46 AM ESTCowen reiterated an Outperform rating on Insmed (NASDAQ: INSM), and cut the price target to $34.00 (from $38.00), folloiwng the company's 3Q15 earnings report. INSM reported Q3 EPS of ($0.50) vs consensus ($0.47). Cowen's lower price target on INSM is based on a potential 12 month delay... More
Insmed (INSM) Misses Q3 EPS by 3c
November 6, 2015 9:12 AM ESTInsmed (NASDAQ: INSM) reported Q3 EPS of ($0.50), $0.03 worse than the analyst estimate of ($0.47).
For earnings history and earnings-related data on Insmed (INSM) click here.
... More